Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G P Reynolds

Showing results (31-40 of 187) with videos related to

Pageof 19
Sort By:
Advances in Pharmacology (San Diego, Calif.)|January 1, 1995
New approaches to the drug treatment of schizophreniaG P Reynolds, C Czudek
Journal of Neural Transmission. General Section|January 1, 1993
Hippocampal benzodiazepine receptors in schizophreniaG P Reynolds, D Stroud
Lancet (London, England)|January 10, 1976
Does phenylethylamine cause schizophrenia?M Sandler, G P Reynolds
Journal of Neural Transmission|January 1, 1981
The effects of lisuride and some other dopaminergic agonists on receptor binding in human brainG P Reynolds, P Riederer
International Pharmacopsychiatry|January 1, 1981
Tranylcypromine isomers in the treatment of Parkinson's disease. Biochemical effectsG P Reynolds, P Riederer
Journal of Chromatography|September 11, 1981
Determination of a wide range of urinary amine metabolites using a simple high-performance liquid chromatographic techniqueP Riederer, G P Reynolds
Journal of Neurochemistry|July 1, 1990
[3H]nipecotic acid binding to gamma-aminobutyric acid uptake sites in postmortem human brainC Czudek, G P Reynolds
Biochemical Society Transactions|May 1, 1993
Free radical damage in Down's syndrome brainG P Reynolds, A J Cutts
Neuroscience Letters|May 22, 1989
Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominataG B Baker, G P Reynolds
Neuroscience Letters|September 14, 1992
Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's diseaseS J Pearson, G P Reynolds
Pageof 19

Showing results (31-40 of 187) with videos related to

Sort By:
Pageof 19
Advances in Pharmacology (San Diego, Calif.)|January 1, 1995
New approaches to the drug treatment of schizophreniaG P Reynolds, C Czudek
Journal of Neural Transmission. General Section|January 1, 1993
Hippocampal benzodiazepine receptors in schizophreniaG P Reynolds, D Stroud
Lancet (London, England)|January 10, 1976
Does phenylethylamine cause schizophrenia?M Sandler, G P Reynolds
Journal of Neural Transmission|January 1, 1981
The effects of lisuride and some other dopaminergic agonists on receptor binding in human brainG P Reynolds, P Riederer
International Pharmacopsychiatry|January 1, 1981
Tranylcypromine isomers in the treatment of Parkinson's disease. Biochemical effectsG P Reynolds, P Riederer
Journal of Chromatography|September 11, 1981
Determination of a wide range of urinary amine metabolites using a simple high-performance liquid chromatographic techniqueP Riederer, G P Reynolds
Journal of Neurochemistry|July 1, 1990
[3H]nipecotic acid binding to gamma-aminobutyric acid uptake sites in postmortem human brainC Czudek, G P Reynolds
Biochemical Society Transactions|May 1, 1993
Free radical damage in Down's syndrome brainG P Reynolds, A J Cutts
Neuroscience Letters|May 22, 1989
Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominataG B Baker, G P Reynolds
Neuroscience Letters|September 14, 1992
Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's diseaseS J Pearson, G P Reynolds
Pageof 19